These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2696 related articles for article (PubMed ID: 23954314)

  • 21. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
    Rivière P; D'Haens G; Peyrin-Biroulet L; Baert F; Lambrecht G; Pariente B; Bossuyt P; Buisson A; Oldenburg B; Vermeire S; Laharie D
    Am J Gastroenterol; 2021 Jan; 116(1):134-141. PubMed ID: 33177349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
    Geboes K; Rutgeerts P; Opdenakker G; Olson A; Patel K; Wagner CL; Marano CW
    Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy.
    Hall B; Holleran G; Chin JL; Smith S; Ryan B; Mahmud N; McNamara D
    J Crohns Colitis; 2014 Dec; 8(12):1601-9. PubMed ID: 25257546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD.
    Sipponen T; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2010 Dec; 16(12):2131-6. PubMed ID: 20848462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
    Colombel JF; Sandborn WJ; Allez M; Dupas JL; Dewit O; D'Haens G; Bouhnik Y; Parker G; Pierre-Louis B; Hébuterne X
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):423-31.e1. PubMed ID: 24184736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.
    D'Haens G; Kelly O; Battat R; Silverberg MS; Laharie D; Louis E; Savarino E; Bodini G; Yarur A; Boland BS; Afif W; Li XJ; Hale M; Ho J; Kondragunta V; Huang B; Kuy C; Okada L; Hester KD; Bray KR; Mimms L; Jain A; Singh S; Collins A; Valasek MA; Sandborn WJ; Vermeire S; Dulai PS
    Gastroenterology; 2020 Feb; 158(3):515-526.e10. PubMed ID: 31711925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease.
    Narula N; Wong ECL; Colombel JF; Sandborn WJ; Ferrante M; Marshall JK; Reinisch W; Dulai PS
    J Crohns Colitis; 2022 May; 16(4):616-624. PubMed ID: 34664635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
    Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.
    Mantzaris GJ; Christidou A; Sfakianakis M; Roussos A; Koilakou S; Petraki K; Polyzou P
    Inflamm Bowel Dis; 2009 Mar; 15(3):375-82. PubMed ID: 19009634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
    Kiss LS; Szamosi T; Molnár T; Miheller P; Lakatos L; Vincze A; Palatka K; Bartha Z; Gasztonyi B; Salamon A; Horváth G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovász BD; Végh Z; Golovics PA; Szathmári M; Papp M; Lakatos PL
    Orv Hetil; 2011 Sep; 152(36):1433-42. PubMed ID: 21865144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementation of the simple endoscopic activity score in crohn's disease.
    Koutroumpakis E; Katsanos KH
    Saudi J Gastroenterol; 2016; 22(3):183-91. PubMed ID: 27184635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol.
    Hébuterne X; Lémann M; Bouhnik Y; Dewit O; Dupas JL; Mross M; D'Haens G; Mitchev K; Ernault É; Vermeire S; Brixi-Benmansour H; Moreels TG; Mary JY; Marteau P; Colombel JF
    Gut; 2013 Feb; 62(2):201-8. PubMed ID: 22525883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
    Kiss LS; Szamosi T; Molnar T; Miheller P; Lakatos L; Vincze A; Palatka K; Barta Z; Gasztonyi B; Salamon A; Horvath G; Tóth GT; Farkas K; Banai J; Tulassay Z; Nagy F; Szenes M; Veres G; Lovasz BD; Vegh Z; Golovics PA; Szathmari M; Papp M; Lakatos PL;
    Aliment Pharmacol Ther; 2011 Oct; 34(8):911-22. PubMed ID: 21883326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease.
    Bouguen G; Levesque BG; Pola S; Evans E; Sandborn WJ
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):978-85. PubMed ID: 24246770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn's disease.
    Grover Z; Burgess C; Muir R; Reilly C; Lewindon PJ
    J Crohns Colitis; 2016 Oct; 10(10):1159-64. PubMed ID: 26980840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of azathioprine in mild or moderate relapse in Crohn's disease: clinical and endoscopic evaluation.
    Murakami Y; Matsui T; Hirai F; Takatsu N; Takaki Y; Nagahama T; Hisabe T; Beppu T; Miyaoka M; Maki S; Takeichi M; Nishimura T; Ueki T; Yao K
    Dig Endosc; 2010 Jan; 22(1):25-32. PubMed ID: 20078661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 135.